Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche discontinued the commercial and clinical use of Elevidys after two cases of fatal acute liver failure. The Swiss ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Former club captain Barry Roche leaves Morecambe after 17 years at the Shrimps that spanned both playing and coaching roles.

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

Roche (SIX:ROG) shares dropped 2% on Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...